Last A$0.01 AUD
Change Today 0.00 / 0.00%
Volume 9.0K
AVX On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 6:23 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

avexa ltd (AVX) Snapshot

Open
A$0.01
Previous Close
A$0.01
Day High
A$0.01
Day Low
A$0.01
52 Week High
10/29/14 - A$0.03
52 Week Low
07/11/14 - A$0.01
Market Cap
13.0M
Average Volume 10 Days
240.4K
EPS TTM
A$-0.0028
Shares Outstanding
925.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AVEXA LTD (AVX)

Related News

No related news articles were found.

avexa ltd (AVX) Related Businessweek News

No Related Businessweek News Found

avexa ltd (AVX) Details

Avexa Limited, a biotechnology company, is engaged in the research and development, and commercialization of anti-infective pharmaceutical programs and projects for the treatment of human immunodeficiency virus (HIV). The company provides apricitabine, a nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. It also offers Integrase, an anti-retroviral drug; and antibiotics. In addition, the company owns the North Pratt coal mine located in North Pratt, Alabama. Avexa Limited was founded in 2004 and is based in Hawthorn East, Australia.

5 Employees
Last Reported Date: 08/28/14
Founded in 2004

avexa ltd (AVX) Top Compensated Officers

Interim Chief Executive Officer and Chief Sci...
Total Annual Compensation: A$202.6K
Head of Finance and Financial Controller
Total Annual Compensation: A$152.0K
Head of Drug Development
Total Annual Compensation: A$166.3K
Compensation as of Fiscal Year 2014.

avexa ltd (AVX) Key Developments

Avexa Ltd., Annual General Meeting, Nov 24, 2014

Avexa Ltd., Annual General Meeting, Nov 24, 2014., at 11:00 AUS Eastern Standard Time. Location: KPMG, 147 Collins Street. Agenda: To receive and consider the financial report, the directors' report and the auditor's report of Avexa for the financial year ended 30 June 2014; to approve the adoption of remuneration report; to approve the re-election of Director Mr. Iain Kirkwood; to approve the amendment to constitution; and to approve the additional 10% placement facility.

Avexa Ltd Announces Audited Consolidated Earnings Results for the Year Ended June 30, 2014

Avexa Ltd. announced audited consolidated earnings results for the year ended June 30, 2014. For the period, the company reported revenue from operating activities of $295,000 compared to $617,000 a year ago. Loss from operating activities was $2,566,000 compared to $3,563,000 a year ago. Loss from operations for the period was $2,897,000 compared to $2,977,000 a year ago. Loss attributable to owners of the company was $2,897,000 compared to $2,977,000 a year ago. Basic and diluted earnings per share were $0.33 compared to $0.35 a year ago. Net cash used in operating activities was $1,688,000 compared to $2,681,000 a year ago. Payments for property, plant and equipment was $20,000 compared to $10,000 a year ago.

Avexa Ltd. Auditor Raises 'Going Concern' Doubt

Avexa Ltd. filed its Annual on Aug 28, 2014 for the period ending Jun 30, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVX:AU A$0.01 AUD 0.00

AVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $59.15 USD -0.01
Gilead Sciences Inc $91.29 USD +1.84
Merck & Co Inc $57.46 USD +0.25
View Industry Companies
 

Industry Analysis

AVX

Industry Average

Valuation AVX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 37.7x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEXA LTD, please visit www.avexa.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.